Methylene Blue

The VerdictLOW CONVICTION

Methylene blue isn't a supplement, it's a hospital drug, and mixing it with antidepressants can be dangerous.

Check your shelf. If you have methylene blue and you take any antidepressant, stop and talk to a doctor before the next dose. It is an MAOI, and the combination can cause serotonin syndrome.

Every solid study is for hospital uses given by IV; there are zero good studies for memory, energy, or focus in healthy people. 2) It's an MAOI, so combining it with common antidepressants can trigger a dangerous reaction. 3) Treat it as a prescription drug, not a supplement, and if it's in your stack and you take an antidepressant, talk to a doctor.

That's the general answer. Your stack is different.

Check your whole stack

Tonight, check your supplement shelf. If there's a bottle of methylene blue and you take any antidepressant, stop and talk to a doctor before the next dose.

Methylene blue is an MAOI. Combined with common antidepressants (SSRIs, SNRIs), it can cause serotonin syndrome, a genuine medical emergency.

Takes 2 minutes. The interaction is the part most people never knew about.

The Protocol

There is no evidence-based consumer protocol for methylene blue. The dosing below is clinical (drug) context for understanding only, not a self-administration guide. Real uses are intravenous and doctor-administered.

Use	Dose	Route / Setting	Notes
Methemoglobinemia (antidote)	~1-2 mg/kg	IV, acute, clinician-given	FDA-approved drug indication
Vasoplegic / septic shock (rescue pressor)	~1-2 mg/kg bolus ± infusion	IV, intensive care	Raises blood pressure; protocol-dependent
Consumer "nootropic / mitochondrial"	No evidence-based dose	Oral OTC (purity often unverified)	No efficacy trials support this use

Forms

Pharmaceutical IV (USP)

~100% (IV)

Methemoglobinemia, shock. Clinician-controlled, purity assured.

"USP" consumer drops

no human data for the brain use

Marketed nootropic. Purity rarely independently verified.

Aquarium / industrial

NOT for humans

Nothing. Contaminant risk. People genuinely buy this by mistake.

The one honest "absorption tip" is that the cheapest products on the market are not certified for human consumption.

Safety & Interactions

SSRIs, SNRIs, TCAs, MAOIs — SEVERE

Methylene blue is a potent MAO inhibitor. Combined with serotonergic antidepressants it can cause serotonin syndrome, which can be fatal. Avoid completely.

Serotonergic opioids (tramadol, meperidine), triptans, St John's Wort — SEVERE

Same serotonin syndrome risk. This is a do-not-combine situation, not a "monitor" one.

G6PD deficiency — CONTRAINDICATED

Can cause hemolytic anemia, and the antidote effect can also fail in these patients.

Dose ceiling — the biphasic paradox

Methylene blue treats methemoglobinemia at low dose and causes it at high dose. Therapeutic dosing is below ~2 mg/kg; above ~7 mg/kg, serious adverse effects appear. There is no "more is better" zone.

Pregnancy — avoid

Fetal harm has been reported historically.

Upper limit: none established, because methylene blue is a drug, not a nutrient. The relevant ceiling is the pharmacological toxicity threshold, not a dietary limit. Expect blue-green urine and possible blue staining of skin or mouth (cosmetic, but startling).

Conviction

LOW-to-MODERATE

The verdict splits hard by who's using it and why. As an IV drug for methemoglobinemia it's well established. As a rescue pressor in shock it reliably raises blood pressure but hasn't been shown to save lives. As a consumer brain or longevity supplement, the evidence is essentially absent and partly contradictory.

Methemoglobinemia antidote (IV drug) HIGH

Vasoplegia / shock hemodynamics (IV) MODERATE

Septic shock mortality (IV) LOW-MOD

Surgical dye / lymph-node harvest MODERATE

Consumer nootropic / mitochondrial / longevity LOW-to-NONE

What would change this?

For the consumer claim, an independent, double-blind, placebo-controlled trial of at least 150 healthy adults taking pharmaceutical-grade methylene blue at a fixed dose for 12+ weeks, with a real memory test as the main outcome plus a brain-blood-flow safety check, showing a meaningful benefit without reducing blood flow, would move healthy-adult cognition up from "essentially none." For septic shock, a large (400+) double-blind trial with survival as the primary endpoint would lift that verdict toward MODERATE.

Worth Your Money?

Weekly costAbout £2–£6 per week for consumer drops.

Worth it ifNothing on the consumer side. The legitimate uses are emergency hospital treatments handled by a doctor, not something you buy off a shelf.

Lower priority ifAlmost anywhere else is a better first spend. If focus or energy is the goal, your money goes further on fixing sleep, timing your caffeine, and getting training and protein consistent than on an unproven, risky drug.

Skip

Go Deeper

Want to stop wasting money on supplements that don't work, and avoid the ones that can hurt you? The Verdict reviews one every week, free.

Join The Verdict — free

Claims vs Evidence — See What the Research Found

What People Claim

The biohacker pitch is that methylene blue is a "mitochondrial enhancer." The mechanism is real on paper: at low concentrations it can act as a backup electron carrier inside the cell's power plants, the mitochondria. From there the marketing extends to "more cellular energy," "sharper focus and memory," "neuroprotection," and "anti-aging."

"A cheap, simple blue liquid that upgrades your mitochondria, clears brain fog, and slows aging, an insider longevity secret."

Stated fairly, the appeal makes sense: it's inexpensive, dramatic-looking, and the cell-biology story sounds sophisticated. What the pitch leaves out is what methylene blue actually is, and what happened when the brain claim was put to the test.

What the Evidence Actually Shows

The literature sweep returned 40 meta-analyses and systematic reviews. Every credible efficacy signal is a hospital drug use. Not one was for cognition, energy, or longevity in healthy adults. That absence is the finding.

Claim / Use	Strength	What the data shows
Methemoglobinemia reversal (IV)	STRONG	Established FDA drug indication.
Raise blood pressure in shock (IV)	MODERATE	Reliable MAP increase (Pasin 2013, N=174; 2025, N=257).
Survival in septic shock (IV)	WEAK-MOD	Uncertain; GRADE low (2024 N=302; 2026 N=441).
Surgical lymph-node dye / harvest	MODERATE	More nodes harvested (rectal MA N=343).
Post-op pain (hemorrhoid / pilonidal / mucositis)	MODERATE	Less pain, fewer recurrences (N=598 / 677 / 432).
Discogenic back pain (injection)	WEAK-MOD	Pain reduced, only 3 small trials.
Cognition / focus (healthy adults)	DEBUNKED-BY-ABSENCE	Zero supportive trials; Alzheimer's Phase 3 (n=891) failed.
"Improves brain blood flow"	BACKWARDS	Imaging shows ~8% reduction at memory doses.

Note: retrieved meta-analyses were abstract-only, so effect directions are reported rather than precise pooled magnitudes. Landmark consumer-claim items (Alzheimer's Phase 3 failure, brain-blood-flow study) are flagged as unverified in the source list below.

The Full Picture — Mechanism, Debate & Nuance

How It Works

Methylene blue is a redox-cycling dye, and its behavior flips with dose. At low dose it hands electrons to hemoglobin, converting the non-functional form back to the kind that carries oxygen. That's the antidote mechanism, and it's why it's approved for methemoglobinemia. In shock, it blocks the nitric oxide pathway that makes blood vessels relax, so it clamps down dilation and raises blood pressure when standard drugs have failed.

The "nootropic" story rests on a third property: at low concentrations it can shuttle electrons directly into the cell's energy chain, bypassing damaged parts. Interesting cell biology, but the jump to an intact human brain fails. When tested in people, the flagship brain trial was negative and imaging showed reduced, not improved, blood flow at memory doses.

One feature dominates safety: there is no "more is better." The same drug that treats methemoglobinemia at low dose causes it at high dose. It's a narrow, two-way window that self-dosers aren't equipped to respect.

The Debate

Does raising blood pressure mean it works?

Shock meta-analyses

Methylene blue reliably raises mean arterial pressure.

Same / adjacent analyses

Survival is not clearly improved (GRADE low certainty).

A surrogate (blood pressure) moves while the outcome that matters (living) doesn't clearly follow. Real hemodynamic effect, unproven clinical benefit.

Test tube vs living brain

Cell / animal models

Boosts mitochondrial respiration and memory.

Human imaging + LMTM Phase 3

Cuts brain blood flow ~8%; Alzheimer's trial (n=891) failed.

The mechanism that sounds best is the one that reverses in real people. The narrative outran, and was then contradicted by, the trial data.

Honest Limitations

Wrong delivery, wrong population

The credible evidence is intravenous, acute, doctor-given, in sick patients. The consumer is taking oral drops, chronically, while healthy. None of the supporting evidence transfers.

Product quality

No human pharmacology study validates a consumer product for the brain use case, and the cheapest products are aquarium or industrial dye not certified for people.

Abstract-only evidence base

The retrieved reviews were abstract-only, so this review reports the direction of effects rather than precise pooled numbers.

The Nuance

Methylene blue is the cleanest "real drug sold as a supplement" case there is. Unlike DHEA (a hormone) or red yeast rice (which contains a statin), it has no pretense of being a nutrient at all. It was a textile dye, then the first synthetic antimalarial, and is now a hospital drug. There is genuinely no food-first alternative, because it was never food.

What doesn't work

"Improves brain blood flow and focus" — human imaging shows it reduces brain blood flow at memory doses. The marketed mechanism runs backwards in people.
"A proven anti-aging nootropic" — no supportive human efficacy trials in healthy adults, and the best test (Alzheimer's Phase 3, n=891) failed.
"Pharmaceutical grade means it's safe to self-dose" — purity isn't the risk. The MAOI interaction and the two-way toxicity window are, and a clean label fixes neither.

Sources

Pruna A, et al. (2024). Methylene Blue Reduces Mortality in Critically Ill and Perioperative Patients: a meta-analysis of 11 RCTs, N=556. MAP raised as adjuvant pressor. PMID 37880041.
(2024). Methylene Blue in Septic Shock: SR and MA, N=302, GRADE low; benefit uncertain. PMID 38904978.
(2026). Methylene Blue for Septic Shock: SR and MA, 15 studies, N=441; mortality not clearly improved. PMID 39574288.
Pasin L, et al. (2013). Methylene blue as a vasopressor: meta-analysis of 5 RCTs, N=174; MAP raised at 1 hour. PMID 23432501.
Yu B, et al. (2021). Intradiskal Injection of Methylene Blue for Discogenic Back Pain: MA of 3 RCTs; pain reduced. PMID 33477188.
(2023). Methylene blue to improve lymph node harvest in rectal cancer surgery: SR and MA, N=343. PMID 36933141.
Lu G, et al. (2018). Methylene blue in the treatment of malaria: a systematic review. PMID 29690878.
LMTM (methylthioninium) Phase 3 in Alzheimer's disease, n=891, did not meet primary endpoints. [cite-unverified] Preflight-sourced.
Methylene blue ~8% reduction in human cerebral blood flow at memory doses, J Cereb Blood Flow Metab, 2023. [cite-unverified] Preflight-sourced.
StatPearls (NBK557593), Methylene Blue: MAOI / serotonin syndrome warning, G6PD contraindication, biphasic dose-response, methemoglobinemia indication. [cite-unverified] Preflight-sourced.